GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » St Jude Medical Inc (NYSE:STJ) » Definitions » EBITDA

St Jude Medical (St Jude Medical) EBITDA : $1,290 Mil (TTM As of Sep. 2016)


View and export this data going back to 1977. Start your Free Trial

What is St Jude Medical EBITDA?

St Jude Medical's EBITDA for the three months ended in Sep. 2016 was $390 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2016 was $1,290 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

St Jude Medical's EBITDA per Share for the three months ended in Sep. 2016 was $1.35. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2016 was $4.48.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


St Jude Medical EBITDA Historical Data

The historical data trend for St Jude Medical's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

St Jude Medical EBITDA Chart

St Jude Medical Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,385.00 1,362.00 1,162.00 1,463.00 1,365.00

St Jude Medical Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 360.00 206.00 279.00 415.00 390.00

Competitive Comparison of St Jude Medical's EBITDA

For the Medical Devices subindustry, St Jude Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


St Jude Medical's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, St Jude Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where St Jude Medical's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

St Jude Medical's EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

St Jude Medical's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2015, St Jude Medical's EBITDA was $1,365 Mil.

St Jude Medical's EBITDA for the quarter that ended in Sep. 2016 is calculated as

St Jude Medical's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2016, St Jude Medical's EBITDA was $390 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,290 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

St Jude Medical  (NYSE:STJ) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


St Jude Medical EBITDA Related Terms

Thank you for viewing the detailed overview of St Jude Medical's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


St Jude Medical (St Jude Medical) Business Description

Traded in Other Exchanges
N/A
Address
St Jude Medical Inc was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician pro
Executives
Jeff Fecho officer: VP, Global Quality ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Philip Ebeling officer: VP, Chief Technology Officer INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BLVD., SUITE 1600, GOLDEN VALLEY MN 55416
Donald Zurbay officer: VP Finance and CFO C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Michael A Rocca director C/O LIGAND PHARMACEUTICALS INCORPORATED, 10275 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Barbara B Hill director
Wendy L Yarno director
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John C Heinmiller officer: Executive Vice President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
John W Brown director STRYKER CORP, 2725 FAIRFIELD ROAD, KALAMAZOO MI 49002
David C Dvorak director C/O ZIMMER INC, PO BOX 708, WARSAW IN 46580
Michael T Rousseau director, officer: Director, President and CEO ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Eric S Fain officer: Group President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Joel Becker officer: President, Americas ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Rohan Hoare officer: President - NMD 100 CYBERONICS BLVD, HOUSTON TX 77058

St Jude Medical (St Jude Medical) Headlines

From GuruFocus

Richard Perry Buys St. Jude

By Sydnee Gatewood Sydnee Gatewood 08-15-2016

Mairs & Power Growth Fund 3rd Quarter Results

By Holly LaFon Holly LaFon 10-31-2016

Richard Perry Exits AIG, Time Warner

By Tiziano Frateschi Tiziano Frateschi 11-14-2016